PAVmed, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70387R4039
USD
0.34
0.01 (3.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About PAVmed, Inc. stock-summary
stock-summary
PAVmed, Inc.
Pharmaceuticals & Biotechnology
PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of products. The Company's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The Company is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The Company is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.
Company Coordinates stock-summary
Company Details
1 Grand Central Terminal Ste 4600 , NEW YORK NY : 10017-5743
stock-summary
Tel: 1 212 94943191 814 2414138
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (3.43%)

Foreign Institutions

Held by 6 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lishan Aklog
Chairman of the Board, Chief Executive Officer
Mr. Michael Glennon
Independent Vice Chairman of the Board
Dr. David Battleman
Independent Director
Dr. James Cox
Independent Director
Mr. Ronald Sparks
Independent Director
Mr. David Weild
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

0.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.08

stock-summary
Return on Equity

136.75%

stock-summary
Price to Book

0.23